By Jane Lewis
A prospective community-based study of almost half a million people in the UK has identified new clinical and genetic determinants of varicose veins, including increased height, reports new research in Circulation.
The author of an accompanying editorial described the study as ‘the largest and most comprehensive epidemiologic and genetic study of varicose veins to date,’ and complimented the authors on this important contribution.
Speaking to Medicine Today, Associate Professor Laurencia Villalba, Head, Vascular Surgery, Illawarra and Shoalhaven Health District, NSW, and founder of the Vascular Care Centre in Wollongong, said the study was ‘a game-changer’.
‘It shows us what modern technology can achieve in helping us better understand the genetic and environmental risk factors of chronic venous insufficiency, a pathology that affects 30 to 40% of the world population and represents a significant burden to society.’
Using data from 493,519 individuals in the UK Biobank – a nationwide longitudinal cohort study of 40 to 69-year-olds – and a range of different methods including machine learning analyses, researchers identified several risk factors for varicose veins. These included the accepted factors of age, obesity, pregnancy and history of deep vein thrombosis (DVT), previously debatable predictors such as hormone replacement therapy and length of education, and novel factors such as history of cellulitis and surgery on leg arteries.
Increased height and leg bioimpedance were both independently associated with varicose vein risk, suggesting a link between high-volume venous reflux, increased hydrostatic pressure and resulting venous hypertension, the researchers wrote. Mendelian randomisation confirmed a causal role of greater height in varicose vein development, and a strong genetic correlation between varicose veins and DVT was also demonstrated.
The authors said their study substantially extended understanding of the genetic and environmental bases of varicose veins, setting a path for identification of new therapeutic targets.
Associate Professor Villalba said it was still very early days and not yet clear how these findings would assist clinicians in the short term. However, she said, ‘the possibilities are endless and it’s only a matter of time until we are able to understand not only how the biological pathways work, but also how we can manipulate them for clinical benefit.’
Circulation 2018; 138: 00-00; doi: 10.1161/CIRCULATIONAHA.118.035584.
Circulation 2018; 138: 00-00; doi: 10.1161/CIRCULATIONAHA.118.037219.